MK-1084 / Merck (MSD), Otsuka 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-1084 / Merck (MSD), Otsuka
MK-1084-004, NCT06345729: A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50%

Recruiting
3
600
US, RoW
MK-1084, Placebo, Pembrolizumab, MK-3475, KEYTRUDA ®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
02/29
02/31
MK-1084-001, NCT05067283: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors

Recruiting
1
830
Europe, Canada, Japan, US, RoW
MK-1084, Pembrolizumab, KEYTRUDA®, MK-3475, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Merck Sharp & Dohme LLC
Advanced Solid Tumors
08/26
08/26
MK-0472-001, NCT05853367: Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors

Recruiting
1
178
Europe, Canada, US
MK-0472, Pembrolizumab, MK-3475, Keytruda®, MK-1084
Merck Sharp & Dohme LLC
Metastatic Solid Tumors, Advanced Solid Tumors
02/28
02/28

Download Options